Catalyst Funds Management Pty Ltd acquired a new position in shares of Waters Co. (NYSE:WAT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,600 shares of the medical instruments supplier's stock, valued at approximately $594,000.
A number of other hedge funds and other institutional investors have also made changes to their positions in WAT. Wealthfront Advisers LLC increased its stake in Waters by 106,144.4% in the 4th quarter. Wealthfront Advisers LLC now owns 3,087,461 shares of the medical instruments supplier's stock valued at $1,145,386,000 after buying an additional 3,084,555 shares during the last quarter. Madison Investment Advisors LLC acquired a new stake in Waters in the 4th quarter valued at $104,645,000. Principal Financial Group Inc. increased its stake in Waters by 70.7% in the 3rd quarter. Principal Financial Group Inc. now owns 656,019 shares of the medical instruments supplier's stock valued at $236,095,000 after buying an additional 271,804 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in Waters in the 4th quarter valued at $42,114,000. Finally, Raymond James Financial Inc. acquired a new stake in Waters in the 4th quarter valued at $40,404,000. 94.01% of the stock is currently owned by institutional investors and hedge funds.
Waters Trading Down 1.2 %
Shares of WAT traded down $4.69 during trading hours on Wednesday, hitting $377.46. 42,339 shares of the stock were exchanged, compared to its average volume of 435,703. Waters Co. has a fifty-two week low of $279.24 and a fifty-two week high of $423.56. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.94 and a quick ratio of 0.65. The business has a 50-day moving average of $391.36 and a 200-day moving average of $370.97. The firm has a market capitalization of $22.43 billion, a P/E ratio of 35.25, a price-to-earnings-growth ratio of 3.79 and a beta of 1.00.
Waters (NYSE:WAT - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share for the quarter, topping the consensus estimate of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. On average, research analysts expect that Waters Co. will post 12.86 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on WAT. Wells Fargo & Company lifted their price objective on shares of Waters from $415.00 to $420.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Bank of America reduced their target price on shares of Waters from $430.00 to $410.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. StockNews.com downgraded shares of Waters from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Sanford C. Bernstein raised shares of Waters from a "market perform" rating to an "outperform" rating and set a $430.00 price objective for the company in a report on Friday, January 10th. Finally, UBS Group boosted their price objective on shares of Waters from $405.00 to $410.00 and gave the company a "neutral" rating in a report on Thursday, February 13th. Eleven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Waters currently has an average rating of "Hold" and a consensus target price of $391.07.
View Our Latest Analysis on WAT
About Waters
(
Free Report)
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Further Reading
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
